These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30393586)

  • 1. Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer.
    Liu Z; Zhu Y; Xu L; Zhang J; Xie H; Fu H; Zhou Q; Chang Y; Dai B; Xu J
    Oncoimmunology; 2018; 7(9):e1474317. PubMed ID: 30393586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Xie H; Fu Q; Dai B; Ye D; Xu J
    Clin Cancer Res; 2018 Jul; 24(13):3069-3078. PubMed ID: 29514839
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients.
    Bo X; Wang J; Suo T; Ni X; Liu H; Shen S; Li M; Wang Y; Liu H; Xu J
    BMC Cancer; 2018 Mar; 18(1):313. PubMed ID: 29562907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients.
    Jin S; Zeng H; Liu Z; Jin K; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Xu L; Xu J; Wang Z; Zhu Y
    Ann Surg Oncol; 2022 Apr; 29(4):2495-2503. PubMed ID: 35000080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer.
    Zhou L; Xu L; Chen L; Fu Q; Liu Z; Chang Y; Lin Z; Xu J
    Oncoimmunology; 2017; 6(4):e1293211. PubMed ID: 28507798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
    Eckstein M; Strissel P; Strick R; Weyerer V; Wirtz R; Pfannstiel C; Wullweber A; Lange F; Erben P; Stoehr R; Bertz S; Geppert CI; Fuhrich N; Taubert H; Wach S; Breyer J; Otto W; Burger M; Bolenz C; Keck B; Wullich B; Hartmann A; Sikic D;
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
    Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
    Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19
    Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
    Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
    Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
    Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer.
    Zhou Q; Zhang H; Wang Z; Zeng H; Liu Z; Huang Q; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Dai B; Guo J; Zhu Y; Xu L; Xu J
    Int J Cancer; 2020 Dec; 147(12):3539-3549. PubMed ID: 32734613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral TIGIT
    Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma.
    Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Wang Z; Xie H; Dai B; Xu J; Ye D
    Ann Surg Oncol; 2017 May; 24(5):1435-1442. PubMed ID: 27896514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor clinical outcomes and immunoevasive contexture in SIRPα
    Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
    Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating IL-17A
    Wang Z; Zhou Q; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Zhu Y; Xu L; Dai B; Liu L; Guo J; Xu J
    Oncoimmunology; 2020; 9(1):1747332. PubMed ID: 32313725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal LAG-3
    Zeng H; Zhou Q; Wang Z; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Xu L; Dai B; Guo J; Liu L; Zhu Y; Xu J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients.
    Zheng X; Liao X; Nie L; Lin T; Xu H; Yang L; Shen B; Qiu S; Ai J; Wei Q
    Front Cell Dev Biol; 2021; 9():748280. PubMed ID: 35004669
    [No Abstract]   [Full Text] [Related]  

  • 18. Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis.
    Zhang J; Zhu Y; Wang Q; Kong Y; Sheng H; Guo J; Xu J; Dai B
    Urol Oncol; 2020 Feb; 38(2):41.e11-41.e18. PubMed ID: 31383549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
    Xie H; Zhu Y; Zhang J; Liu Z; Fu H; Cao Y; Li G; Shen Y; Dai B; Xu J; Ye D
    BMC Cancer; 2018 May; 18(1):590. PubMed ID: 29793447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral CCR5
    Xiang Z; Zhou Q; Zeng H; Wang Z; Zhang H; Liu Z; Huang Q; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Wang J; Guo J; Xu J
    Oncoimmunology; 2020 Aug; 9(1):1802176. PubMed ID: 32923162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.